toremifene


Also found in: Wikipedia.

toremifene

 [tor´ĕ-mĭ-fēn″]
an analogue of tamoxifen that acts as an estrogen antagonist; used as the citrate salt in palliative treatment of metastatic breast carcinoma, administered orally.

toremifene

/to·re·mi·fene/ (tor´ĕ-mĭ-fēn″) an analogue of tamoxifen that acts as an estrogen antagonist; used as the citrate salt in the palliative treatment of metastatic breast carcinoma.

toremifene

an antineoplastic.
indications It is used to treat advanced breast carcinoma that is not responsive to other therapy in estrogen-receptor-positive patients (usually postmenopausal).
contraindications Known hypersensitivity to this drug and pregnancy prohibit its use.
adverse effects Life-threatening effects are thrombocytopenia and leukopenia. Other adverse effects include altered taste (anorexia), vaginal bleeding, pruritus vulvae, rash, alopecia, chest pain, depression, hypercalcemia, ocular lesions, retinopathy, corneal opacity, and blurred vision (high doses). Common side effects include nausea, vomiting, hot flashes, headache, and light-headedness.

toremifene

Oncology An antiestrogen that may control certain CAs, ↓ recurrence. Cf Tamoxifen.

toremifene

An anti-oestrogen drug used to treat oestrogen-dependent breast cancers that have spread. Most breast cancers are oestrogen-dependent. A brand name is Fareston.
References in periodicals archive ?
002 ([section]) Virus variant Toremifene or subtype [EC.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
The findings open the way for further testing of the drugs, clomiphene and toremifene, against the deadly virus.
Orion Corporation (Orion), the Finnish corporation that developed toremifene, will continue to manufacture and supply Fareston for the US market under an exclusive License and Supply Agreement executed between ProStrakan and Orion.
DNA adducts caused by tamoxifen and toremifene in human microssomal system and lymphocytes in vitro.
Tamoxifen and toremifene cause impairment of learning and memory function in mice.
ORLANDO -- Toremifene citrate, a selective estrogen receptor modulator, increased bone mineral density and improved lipid levels in men receiving androgen-deprivation therapy for advanced prostate cancer, investigators reported at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology.
Agents with anti-estrogenic activity: Aromatase inhibitors including anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone; selective estrogen receptor modulators including raloxifene, tamoxifen, toremifene
Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Age younger than 60 years and amenorrheic for at least 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression, and FSH and estradiol in the postmenopausal range.
Toremifene (Fareston) has properties and side effects similar to tamoxifen but does not seem to increase the risk of endometrial cancer.
Toremifene has an antagonist/agonist profile similar to that of tamoxifen.